Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
TENX
Tenax Therapeutics, Inc.
CAPPED RATING
Tenax Therapeutics, Inc. (TENX) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Overall Rating
1.7
/ 5.0
D+
Value
C+
Factor Score
2.5
/ 5.0
Growth
C-
Factor Score
1.9
/ 5.0
Profitability
C
Factor Score
2.2
/ 5.0
Momentum
D+
Factor Score
1.7
/ 5.0
Revisions
F
Factor Score
0.0
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-1.2
EV / EBITDA
N/A
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-5.3%
Price Return 12M
-76.8%
Catalyst Signal
0.00
Market Cap
$73.8M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-64.2%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | C- (1.9) | C (2.2) | D+ (1.7) | F (0.0) | D+ (1.7) |
| 2026-11-08 | C+ (2.5) | D+ (1.5) | C (2.2) | C- (2.0) | F (0.0) | D+ (1.6) |
| 2026-11-01 | C+ (2.5) | D+ (1.7) | C (2.3) | F (0.4) | F (0.0) | D (1.4) |
| 2026-10-25 | C+ (2.5) | D+ (1.7) | C (2.2) | F (0.4) | F (0.0) | D (1.4) |
| 2026-10-18 | C+ (2.5) | D+ (1.7) | C (2.2) | F (0.4) | F (0.0) | D (1.4) |
Page
1
of
4